LifeStance Health Group, Inc.

Item 5. Other Information.

During our fiscal quarter ended September 30, 2026, six directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) entered into, modified (as to amount, price or timing of trades) or terminated (i) contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information or (ii) non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K).

The following table provides information about the trading plans adopted by certain of our officers and directors during thethree months ended September 30, 2026:

(1)

The Rule 10b5-1 trading plan permits transactions through and including the earlier of (a) the completion of all sales or (b) the date listed in the table. The arrangement also provides automatic expiration in the event of liquidation, dissolution, bankruptcy, insolvency, or death of the adopting person.

(2)

Shares reported within this column include shares subject to limit orders and such orders may not fill if limit order conditions are not met. The actual number of shares sold under the plan will depend on the number of shares withheld or sold to satisfy income tax withholding obligations and on the vesting of certain performance-based equity awards and may vary from the number provided herein. The number of performance-based equity awards included in the plans assumes awards are earned at target.

(3)

Subsequent to September 30, 2026, Mr. Burdick terminated his Rule 10b5-1 trading plan.

(4)

The Rule 10b5-1 trading plan was adopted by the Kimberly Pardo Irrevocable Trust. Mr. Pardo disclaims beneficial ownership of securities held by the Kimberly Pardo Irrevocable Trust except to the extent of his pecuniary interest therein.